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A wide range of topoisomerase-targeted agents are useful clini-
cally, with documented activities in a broad spectrum of human
malignancies (Pommier, 1997). Most of these have been shown to
stabilize the reaction intermediate of the topoisomerase catalytic
cycle, termed the cleavable complex, resulting in DNA cleavage
stimulation and this is considered the molecular basis for their
antitumour activities (Froelich-Ammon and Osheroff, 1995;
Pommier, 1997). These types of agents have been termed topoiso-
merase poisons (Gatto et al, 1999). However, other compounds
have more recently been shown to interfere with topoisomerase
function without stabilizing the cleavable complex and these,
termed catalytic inhibitors, include merbarone (Khélifa and Beck,
1999), bis(dioxopiperazine) derivatives (Ishida et al, 1995) and
certain DNA-interacting agents (Gatto et al, 1999).
Amongst various topoisomerase poisons, a few have been
reported to possess dual inhibitory activities against both topoiso-
merases I and II, including saintopin (Yamashita et al, 1991), into-
plicine (Riou et al, 1991) and TAS-103 (Fortune et al, 2000). All
these dual inhibitors though share DNA intercalating properties
and stabilize cleavable complexes. Indeed, inhibition of the
function of one topoisomerase is frequently compensated for by
alterations in the expression of the other. Furthermore, expression
levels of topoisomerases I and II vary with tumour type (van der
Zee et al, 1991; Hussain et al, 1994). Therefore, targeting both
topoisomerases appears an attractive chemotherapeutic strategy
and in aiming to identify new antitumour compounds with broader
activity spectra, a catalytic inhibitor of both these nuclear enzymes
was considered a potential candidate.
Thus, a research programme was initiated centred on synthe-
sizing chemical modifications of epipodophyllotoxin-based
compounds, using the etoposide skeleton, considering that
enhanced lipophilicity would be associated with increased inter-
action with lipidic cell membranes and improved cellular penetra-
tion. It was hypothesized that such enhanced lipophilicity would
promote an important modification in the compound’s in vivo
distribution, so leading to new epipodophylloid-type compounds
with a novel profile of antitumour activity. F 11782 or 2′′ ,3′′ ,-bis
pentafluorophenoxyacetyl-4′′ ,6′′ -ethylidene-β -D glucoside of 4′ -
phosphate-4′ -demethylepipodophyllotoxin, N-methyl glucamine
salt was selected from this series based on its activity in primary
pharmacological screening and its original mechanistic properties
as a dual catalytic inhibitor of both topoisomerases I and II without
DNA intercalating properties (Perrin et al, 2000).
This report focuses on the in vivo pharmacological profile of
F 11782 against a panel of transplantable tumour models with
different biological properties and chemosensitivities, specifically
the i.v.-implanted murine P388 leukaemia, the s.c.-implanted
B16 and the metastatic i.v.-implanted B16F10 melanoma, and two
human tumour xenografts MX-1 (breast) and LX-1 (lung).
MATERIALS AND METHODS
Drugs
F 11782 (CRPF, Castres, France) was dissolved in a solution
containing 5% Tween in 5% glucose in water (5/95; w/v) for i.p.
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Etoposide (Pierre Fabre Médicament, Castres, France) and camp-
tothecin (Janssen, Noisy Le Grand, France) were solubilized in a
0.9% sodium chloride containing 5% Tween (v/w).
Mice and tumour models
Female hybrid CDF1 (CD2F1/Cr1BR) and C57BL/6 (C57BL/6
NCr1BR) mice (Charles River, St Aubin-les-Elbeuf, France) were
used for implanting the murine P388 leukaemia, and the murine
B16 and B16F10 melanomas (Division of Cancer Treatment,
Tumour Repository, NCI, Frederick, MD, USA), respectively.
Homozygous female athymic nude mice (Ico: Swiss-nu/nu, Iffa
Credo, L’Arbresle, France), were implanted with LX-1 (lung) or
MX-1 (breast) human tumour xenografts (Division of Cancer
Treatment, Tumour Repository, NCI, Frederick, MD, USA).
Animals were handled and cared for in accordance with the Guide
for the Care and Use of Laboratory Animals (National Research
Council, 1996) and the European Directive EEC/86/609, under the
supervision of authorized investigators.
Experimental chemotherapy
All experiments were conducted in compliance with French regu-
lations and CRPF ethical committee guidelines, based on the
UKCCCR guidelines for the welfare of animals in experimental
neoplasia, as detailed previously (Kruczynski et al, 1998). 106
P388 cells/mouse were implanted i.v. into C2DF1 mice on day
zero. For the B16 model, 0.5 ml of a tumour brei at 1 g/ml, made
by disrupting and homogenizing tumour fragments in sterile
0.9% sodium chloride were inoculated s.c. into mice on day zero.
Fragments of human tumour xenografts were implanted into Swiss
mice by trocar and allowed to increase to a median value of
100–300 and 46–150 mm3 for the advanced-stage and early-stage
disease, respectively. After randomization in treatment cages, test
compounds were administered according to various schedules
and/or routes. B16F10 cells maintained in vitro in RPMI medium
supplemented with 10% fetal calf serum, 4 mM L-glutamine,
1.25 µ g/ml fungizone and 100 µ g/ml penicillin-streptomycin,
were implanted i.v. into the tail vein of mice, and test compounds
were administered the following day. In each chemotherapy trial,
mice were checked daily, with any adverse clinical reactions noted
and deaths recorded. Mice were weighed 2–4 times weekly during
treatments and once weekly thereafter. Tumours were measured by
callipers twice weekly and tumour volumes (mm3) were estimated
as = 0.5 (length × width2). Results are presented for experiments
involving 7–30 mice per experimental group according to the
model used.
Evaluations of antitumour activity
Life span
An increase of survival was defined as the (median survival of
treated mice/median survival of control mice) × 100, (T/Cls %).
Survival curves of treated and control groups of B16 tumour-
bearing mice were statistically compared using the Log-rank test.
Tumour growth
Treatment efficacy was assessed in terms of the compound’s
effects on the tumour volumes of tumour-bearing relative to
control vehicle-treated mice. Four evaluation criteria were used in
parallel: (i) Growth inhibition, calculated as the ratio of the median
tumour volumes of drug-treated versus control groups: T/C, % =
(median tumour volume of drug-treated group on day X /median
tumour volume of control group on day X) × 100, the optimal
value, being the minimal T/C ratio which reflects the maximal
tumour growth inhibition achieved (Hendriks et al, 1992); (ii)
Specific tumour growth delay (SGD), calculated as follows: for
the B16 model = [Td (drug-treated group) – Td (vehicle-treated
group)]/Td (vehicle-treated group), with Td being the tumour
doubling time of drug-treated and control groups, defined as the
time in days required for the tumour volume to double. For human
tumour xenografts, SGD was defined as the difference in time for
drug-treated and control tumours to reach a given volume, (v),
divided by the time for the control tumours to reach this same
volume v. Thus, SGDv = [Tv (drug-treated group) – Tv (control
group)]/Tv (control group)], with the v value being 1500 mm3 and
500 mm3 for the MX-1 and LX-1 tumour xenografts, respectively,
and Tv being the time for drug-treated or control groups to reach
the given volume v; (iii) Tumour regressions, defined as partial
(PR) if the tumour volume decreased to 50% or less of that at
the start of treatment, without dropping below measurable size
(Plowman et al, 1997); (iv) Relative area under the tumour growth
curve, rAUC (%), representative of the tumour growth curve as a
whole, reflects the overall effect of a test compound over time (cf.
Kruczynski et al, 1998). rAUC = median [(area under the tumour
growth curve of an individual experimental mouse/median area
under the tumour growth curve of the control group) × 100]. The
more active the compound, the lower the rAUC value. The non-
parametric Mann-Whitney Rank Sum test was used for statistical
comparisons of the respective rAUC population values.
Lung metastatic foci
On day 17 after tumour cell implantation, lungs were quickly
excised, the metastatic foci on the pulmonary surface were
counted. Results of control and drug-treated groups are expressed
as median values.
RESULTS
P388 murine leukaemia
F 11782 demonstrated marked antitumour activity against the i.v.-
implanted P388 leukaemia, given i.p. as a single dose. The optimal
dose, i.e., that inducing the greatest increase of life span, reflected
by a maximal T/Cls ratio with minimal side effects, was 320 mg/-
kg, producing a median T/Cls value of 400%, considered indicative
of a high level of activity (H) by NCI criteria (Table 1), with body
weight loss of only 5.6%. Doses of F 11782 resulting in definite
toxicity were not identified, since those higher than 320 mg/kg
could not be evaluated because of limited solubility and the high
viscosity of F 11782-containing solutions. The reference
compounds studied, etoposide and camptothecin, were also active
against this i.v.-implanted P388 leukaemia, but gave lower optimal
T/Cls values of only 214–243%.
The effects of multiple doses of F 11782 (Table 1), either as four
daily injections (days 1–4), or as intermittent treatments over 2
weeks (days 3, 5, 7, 10, 12 and 14), also provided evidence of a
high level of activity with an increased life span reflected by
maximal T/Cls ratios of 429% and 457%. Using the 2-week
Antitumour activity of F 11782, a dual topoisomerase inhibitor 1517
British Journal of Cancer (2000) 83(11), 1516–1524 © 2000 Cancer Research Campaignschedule, multiple doses of up to 160 mg/kg/injection induced no
major body weight loss (Table 1). However, four daily injections
of 320 mg/kg F 11782 resulted in 14% early deaths, probably
associated with solubility/viscosity problems, which appeared
cumulative with repeated dosing, since at autopsy following the
last treatment whitish deposits were noted within the peritoneal
cavities of treated mice. Six treatments with 320 mg/kg/injection
of F 11782 over two weeks also induced marked weight loss of
28.9% (Table 1) and again at autopsy whitish deposits were
revealed within the peritoneal cavity.
F 11782 was also active against the i.v.-implanted P388
leukaemia, administered i.v. or p.o., in a single dose, inducing an
increased life span reflected by maximal T/Cls ratios of 314% and
143%, respectively (Table 2). Indeed i.v. administration of 150 mg/
kg F 11782 resulted in 3/7 (43%) long-term survivors at 60 days.
No weight loss in excess of 9% was recorded, although one
presumed drug-related death was recorded at 160 mg/kg (Table 2).
The activity of F 11782 using the p.o. route, was greatly
augmented when multiple intermittent treatments were given over
2 weeks, reflected by T/Cls values of 243% and these repeated
doses were associated with body weight losses of only 1–2%
(Table 2).
B16 murine melanoma
Activity was evaluated using a single dose, multiple daily injec-
tions (days 3–6) or intermittent treatments over 2 weeks, i.e., on
days 3, 5, 7, 10, 12 and 14 (Table 3). F 11782 given i.p. as a single
dose significantly increased survival, as assessed by the Log-rank
test (P < 0.001), and at 320 mg/kg was associated with significant
tumour growth inhibition, reflected by an optimal T/C value of 3%
judged, according to NCI criteria, as a high level of activity (T/C
< 10%) and a significant (P < 0.001) rAUC values of 17% (Table
3). Significant tumour growth inhibition was also recorded at
160 mg/kg F 11782, with an optimal T/C value of 24% and an
rAUC value of 27%. Again, doses of F 11782 higher than 320
mg/kg could not be tested because of limited solubility/high
viscosity and therefore toxic doses were not identified. Multiple
daily administrations (on days 3–6) significantly increased
survival (P < 0.001–0.05) at doses of 20, 40 and 80 mg/kg/injec-
tion, associated with marked effects on tumour growth reflected by
significant (≤ 42%) optimal T/C ratios of 29%, 4% and 0.3%,
respectively and significant (P < 0.001) rAUC values of 39%, 26%
and 17%, respectively (Table 3). Again the T/C values of 4% and
0.3% are representative of a high level of activity (T/C < 10%). No
body weight loss in excess of 2.7% was recorded. However, at 160
mg/kg/injection 18% weight loss and some immediate toxic deaths
resulted. Administration of F 11782 as intermittent treatments over
2 weeks had marked antitumour activity against this s.c.-implanted
B16 melanoma, both in terms of increased life span 
(P < 0.001–0.01) and tumour growth inhibition. These effects
were observed at four dose levels, ranging from 20–160 mg/kg
(Table 3 and Figure 1), yielding optimal T/C ratios of 0.2–24%,
with three doses providing a high level of antitumour activity (T/C
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Table 1 Antitumour activity of F 11782 given i.p. as a single or multiple doses against the i.v.-implanted P388 murine leukaemia. Comparison with etoposide
and camptothecin
Test Schedule
Dose (mg/kg)
Max. body weight Presumed drug-related T/Cc(%) Activity
compound (days) Single Total changea (%) [day] deathsb (%) ratingd
F 11782 ‘single dose’ 40 40 –0.7 [4] 0 143 L
(1) 80 80 gain 0 200 H
160 160 –1.9 [4] 0 300 H
320# 320# –5.6 [8] 0 400 H
etoposide ‘single dose’ 20 20 gain 0 157 L
(1) 80 80 –2.3 [4] 0 214 H
160 160 –6.1 [4] 0 243 H
640 640 –11 [4] 86 86 toxic
camptothecin ‘single dose’ 5 5 0.0 [4] 0 157 L
(1) 10 10 –4.9 [4] 0 200 H
20 20 –9.8 [4] 0 214 H
40 40 –13.0 [4] 43 100 toxic
F 11782 ‘1 week’ 5 20 –0.9 [3] 0 143 L
1,2,3,4 20 80 –1.7 [2] 0 229 H
40 160 –1.8 [3] 0 286 H
80 320 –3.0 [2] 0 421 H
160 640 –11.7 [8] 0 429 H
320# 1280 –15.2 [4] 14 86 0
F 11782 “2 weeks” 10 60 –1.8 [12] 0 157 L
3,5,7,10,12,14 20 120 gain 0 257 H
40 240 gain 0 257 H
80 480 –2.7 [5] 0 286 H
160 960 –7.5 [14] 0 457 H
320e 1920 –28.9 [10] 0 143 L
aBody weight changes are maximal weight losses expressed as a percentage of initial body weight. According to NCI criteria, a dose is considered toxic if the
induced body weight loss is >15% of the initial body weight. No body weight loss was recorded in control animals. bA death was presumed drug-related if it
preceded the first death in the solvent-treated group. cT/C = (median survival of drug-treated group/median survival of control group) × 100. dAccording to NCI
standard criteria for the P388 tumour model, 120% ≤ T/C < 175% is the minimal level for activity (L) and T/C ≥ 175% corresponds to a high level of
antileukaemic activity (H); “0” represents a T/C value of < 120% (Venditti, 1981). eHigher doses of F 11782 were not tested because of its limited solubility and
high viscosity in solution. Max. = maximal< 10%). This tumour growth inhibition was also illustrated by
significant (P < 0.001) rAUC values of 1–43%, as well as
markedly significant SGD values of 2.8–6.6 (Table 3), i.e., > 1
according to the criteria of Langdon et al (1994). However, the
highest dose of 160 mg/kg/injection resulted in toxicity with body
weight loss of 27%. Therefore, the optimal tolerated dose of F
11782 given over 2 weeks was 80 mg/kg/injection corresponding
to an optimal total dose of 480 mg/kg, which was 1.5-fold higher
than that which could be given either as a single-dose or as
multiple daily treatments (Table 3). Therefore, intermittent treat-
ments over 2 weeks enabled a higher optimal total dose of F 11782
to be administered and resulted in the highest level of antitumour
activity against this s.c.-implanted B16 model.
A comparative study conducted in parallel showed that etopo-
side, given as intermittent treatments over 2 weeks, induced only
minimal inhibitory activity (T/C of 13%) and an rAUC value
of 15% at 40 mg/kg/injection (Table 3). Increasing the dose to
80 mg/kg/injection resulted in toxicity with body weight loss of
22%, as well as toxic deaths, not though associated with any
solubilization problems (Table 3). Administration of etoposide as
Antitumour activity of F 11782, a dual topoisomerase inhibitor 1519
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Table 2 Effects of the route of administration on the antitumour activity of F 11782 against the i.v.-implanted P388 leukaemiaa
Schedule
Dose (mg/kg)
Route Maximal Presumed T/C (%) Activity
(days) Single Total body weight drug-related [Long-term rating
change (%) deaths (%) survivors,
[day] 60 days]b
‘single dose’ 40 40 i.v. gain 0 114 0
(1) 80 80 i.v. gain 0 186 H
120 120 i.v. –1.5 [4] 0 300 H
150 150 i.v. –6.2 [8] 0 314 [3/7] H
160 160 i.v. –1.2 [4] 14 257 [1/7] H
‘single dose’ 40 40 p.o. gain 0 114 0
(1) 80 80 p.o. gain 0 129 L
160 160 p.o. –1.0 [8] 0 129 L
320# 320 p.o. gain 0 143 L
‘2 weeks’ 2.5 15 p.o. gain 0 100 0
(3,5,7,10,12,14) 10 60 p.o. –2.0 [10] 0 143 L
20 120 p.o. gain 0 129 L
40 240 p.o. –2.8 [10] 0 143 L
80 480 p.o. –9.0 [12] 0 200 H
160 960 p.o. –1.0 [12] 0 243 H
320# 1920 p.o. –2.0 [14] 0 243 H
aSee footnotes to Table 1. bTreated-animals still surviving 60 days after tumour implantation are recorded as long-term survivors.
Table 3 Antitumour activity of F 11782 given i.p. against the s.c.-implanted B16 murine melanoma: comparison with etoposide
Test Schedule Dose Maximal Survival Tumour growth inhibition
compound body weight changea
(days) (mg/kg/inj) (%) [day] Log-rank test Opt.T/Cb (%) [day] SGDc rAUCd (%)
[Mann-Whitney test]
F 11782 ‘single dose’ 80 gain ns 70 [12] 0.0 98 [ns]
(3) 160 –2.5 [5] ns 24 [12] 1.1 27 [***]
320# –4.7 [5] *** 3 [12] 0.6 17 [***]
F 11782 ‘qld× 4’ 10 gain ns 83 [19] <0 98 [ns]
(3,4,5,6) 20 gain * 29 [12] 0.3 39 [***]
40 gain ** 4 [12] 0.3 26 [***]
80 –2.7 [10] *** 0.3 [12] 0.7 17 [***]
160 –18 [10] toxic deathse
F 11782 ‘2 weeks’ 10 gain ns 96 [17] <0 120 [ns]
(3,5,7,10,12,14) 20 gain ** 4 [21] 4.0 30 [***]
40 gain *** 24 [17] 3.3 43 [***]
80 –4.4 [14] *** 3 [21] 6.6 4 [***]
160 –27 [21] ** 0.2 [21] 2.8 1 [***]
etoposide ‘2 weeks’ 10 0.0 [5] * 48 [14] 0.5 68 [*]
(3,5,7,10,12,14) 20 gain ns 42 [17] 0.5 53 [**]
40 –2.7 [10] ns 13 [14] 0.6 15 [***]
80 –22 [12] toxic deaths
aBody weight changes are maximal weight losses expressed as a percentage of intial body weight. No body weight loss was recorded in control animals.
bT/C = (median tumour volume of drug-treated group/median tumour volume of control group) × 100. According to NCI standard criteria for a solid tumour
model, T/C ≤ 42% corresponds to a minimal level of activity (Bissery et al, 1991). cSGD = [Td (drug-treated group) – Td (control group)]/Td control group, with
Td being the time required for the tumour to double in volume. According to NCI/EORTC standard criteria, SGD > 1 corresponds to a minimal level of activity
(Langdon et al, 1994). drAUC = relative area under the tumour growth curve. eToxic deaths, i.e., when treated animals died before controls. ns = P > 0.05;
* = P < 0.05;** = P <0.01;*** = P <0.001. #Higher doses of F 11782 were not tested because of its limited solubility and high viscosity in solution. Opt. = optimal1520 A Kruczynski et al
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Figure 1 Effects of F 11782 given i.p. as intermittent treatments over two weeks (days 3, 5, 7, 10, 12 and 14) at 20, 40, 80 or 160 mg/kg per injection on the
survival (A) and tumour growth (B) of s.c.-grafted B16 melanoma-bearing mice. Initially, 0.5 ml of B16 tumour brei at 1 mg/ml were inoculated s.c. into C57BL/6
mice, and drug treatments were initiated 3 days later. The solid and dotted lines correspond to the F 11782-treated and vehicle-treated groups, respectivelyAntitumour activity of F 11782, a dual topoisomerase inhibitor 1521
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single or multiple daily (days 3–6) doses also provided only
minimal antitumour effects in terms of growth inhibition, as
reflected by optimal T/C ratios of 41% and 20%, and optimal
rAUC values of 66% and 40%, respectively (data not shown).
Experimental B16F10 pulmonary metastases
F 11782 given i.p. in a single dose on the day following tumour
implantation resulted in a marked dose-dependent reduction of
pulmonary B16F10 metastatic foci number in the lungs of mice,
with inhibitions of 66.5, 82.5, 91 and 99% noted at 40, 80, 160 and
320 mg/kg, respectively (data not shown). No body weight loss in
excess of 15% was recorded.
Human MX-1 (breast) and LX-1 (lung) tumour
xenografts
F 11782 exhibited major activity against advanced-stage MX-1
human breast xenografts (Table 4). This activity was obtained
following intermittent i.p. treatments over 2 weeks at doses of 80,
120 and 160 mg/kg/injection. A high level of antitumour activity
resulted from the two highest doses, with definite tumour regres-
sions, reflected by partial regressions lasting from days 33–47 and
29–47 post-tumour implantation, respectively. Optimal T/C ratios
of < 10%, namely 0.8% and 0.1%, also indicated a high level of
activity according to NCI criteria. This antitumour activity was
sustained over time since T/C ratios < 10% were recorded from
day 26 until the end of the experiments on day 47. Highly signifi-
cant (P < 0.001) rAUC measurements resulted from these two
highest doses, as well as at the lower dose of 80 mg/kg/injection,
which was associated with a significant (i.e., > 1) SGD1500 value of
2.3. No body weight loss in excess of 6.5% was noted. Attempts
to evaluate 240 mg/kg/injection produced early deaths (data not
shown), most probably associated with the solubility/high
viscosity problems, as discussed above.
F 11782 showed clearly superior activity to that of etoposide
against similarly staged MX-1 tumour xenografts (see Figure 2
and Table 4). Etoposide exhibited only moderate activity, with
high level of activity being recorded only at the highest dose tested
of 40 mg/kg/injection, which though was toxic being associated
with significant body weight loss of 21%.
The responses of LX-1 human lung xenografts to F 11782 given
i.p. as intermittent treatments over 2 weeks are detailed in Table 4.
Starting treatments when tumours reached a volume range of
46–150 mm3, resulted in definite tumour growth inhibition at 120
and 160 mg/kg F 11782 and rAUC values for the treated animals
significantly (P < 0.001–0.01) lower than those of control mice
(Table 4). Optimal T/C ratios of 41% and 19%, judged significant
(i.e., ≤ 42%) were noted et 120 and 160 mg/kg/injection, respec-
tively and at the higher dose the SGD500 value of 1.9 was signifi-
cant (i.e., > 1) and was associated with body weight loss of only
11.3% (Table 4).
Etoposide, evaluated concurrently, showed moderate activity
against these LX-1 tumours, with significant effects recorded at
the non-toxic dose of 30 mg/kg/injection, reflected by an rAUC
value of 70% and an optimal T/C ratio of 35%. Increasing the
dose, whilst resulting in improved antitumour activity, was associ-
ated with some toxicity involving body weight loss of 16.2%
(Table 4). These results illustrate the superior antitumour activity
of F 11782 relative to etoposide against these early-stage LX-1
tumour xenografts, and this again activity proved more durable
since the optimal T/C values for F 11782 were obtained on days 36
and 39, relative to only day 15 with etoposide.
DISCUSSION
This study has documented major in vivo antitumour activity for
this novel lipophilic epipodophylloid, F 11782, against a panel of
transplantable murine and human tumour models. F 11782 exhib-
ited marked antitumour activity against the i.v.-implanted murine
Table 4 Antitumour activity of F 11782 given i.p. against the s.c.-implanted human MX-1 (breast) and LX-1 (lung) tumour xenografts: comparison with
etoposidea
Model Test Maximal Tumour growth inhibition/regression
compound Dose body weight change
(mg/kg/inj) (%) [day] Opt.T/C (%) [day] SGDvb [PRc, duration in days] rAUC (%) 
[Mann-Whitney test]
Advanced-stage F 11782 40 –2.1 [13] 69 [26] 0.2 113 [ns]
MX-1 80 –6.5 [13] 17 [36] 2.3 27 [***]
(Breast) 120 –4.0 [13] 0.8 [40] [PR, 33–47] 11 [***]
160 –3.4 [15] 0.1 [36] [PR, 29–47] 11 [***]
control gain
etoposide 20 gain 77 [22] 0.2 89 [ns]
30 –8.1 [18] 44 [22] 0.8 48 [**]
40 –21.3 [26] 4 [29] 2.3 22 [***]
control gain
Early-stage F 11782 80 –5.6 [9] 56 [39] 0.1 85 [ns]
LX-1 120 –6.8 [11] 41 [36] 0.4 53 [**]
(Lung) 160 –11.3 [22] 19 [39] 1.9 29 [***]
control –0.4 [11]
etoposide 20 –2.6 [36] 45 [15] 0.5 90 [ns]
30 –6.8 [14] 35 [15] 1.0 70 [*]
40 –16.2 [25] 27 [15] 2.0 45 [***]
control –0.4 [25]
aSee footnotes to Table 3. bSGDv = [Tv (drug-treated group) – Tv (control group)]/Tv (control group), with Tv being the time for treated and control tumours to
reach a given volume v; v being 1500 mm3 and 500 mm3 for the MX-1 and LX-1 models, respectively. cPR = partial tumour regression. Test compounds were
given i.p. as intermittent treatments over two weeks, on days 11, 13, 15, 18, 20, 22, and 7, 9, 11, 14, 16, 18 for the MX-1 and LX-1 tumour models, respectively.
ns = P >0.05; * = P <0.05; ** = P < 0.01; *** = P <0.001.1522 A Kruczynski et al
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Figure 2 Responses of human advanced-stage MX-1 (breast) xenografted tumours to 80, 120 or 160 mg/kg per injection F 11782 (  ) or 20, 30 and 40 mg/kg
per injection etoposide (  ), relative to control vehicle-treated mice (   ). Tumour fragments were implanted s.c. by trocar into athymic mice and, when tumours
had reached a volume of 10–300 mm3, mice were randomized and treatments were given i.p. on days 11, 13, 15, 18, 20 and 22P388 leukaemia in terms of survival prolongation, when given
i.p. as a single treatment over doses ranging from 40–320 mg/kg,
yielding T/Cls ratios of 143–400%, with no associated toxicity.
The maximal T/Cls value of 400%, indicative of a high level of
antileukaemic activity according to NCI criteria (Venditti, 1981),
is 1.6 to 1.9-fold superior to those recorded with etoposide and
camptothecin, and 1.9 to 4-fold superior to those noted with a
series of 10 topoisomerases poisons or inhibitors tested concur-
rently under the same experimental conditions (see Figure 3,
unpublished data).
Intermittent treatments over two weeks permitted administra-
tion of the highest total dosage of F 11782, namely 960 mg/kg,
corresponding to three times the highest single dose. Antitumour
efficacy was recorded over six dose levels of F 11782 using this
intermittent schedule, and over four and five dose levels with the
single-dose or the four daily injections, respectively. Therefore,
intermittent multiple treatments over two weeks appeared the best
schedule for F 11782 in this P388 model.
F 11782 also proved active in this model when administered i.v.
or p.o. A single i.v. dose of 80–150 mg/kg and multiple p.o. doses
(80–320 mg/kg/injection) over two weeks, resulted in a high level
of activity. These repeated oral doses of F 11782 had definite anti-
tumour activity over six dose levels, as well as showing that a 6-
fold higher total dosage could be given thus, without any adverse
side effects. This good overall tolerance to F 11782 suggests that
this novel compound may have a wide therapeutic window. These
results also indicate that F 11782 readily crosses physiological
barriers and is well absorbed by the mouse, auguring well for
clinical studies if similar absorption is achieved in man.
However, drug solubility was a limiting factor in the dose esca-
lation of F 11782 and no frankly toxic doses could be identified.
Therefore, an alternative formulation of F 11782 is required and is
currently being sought.
The s.c.-implanted B16 melanoma was selected on account of
its relatively drug-refractory nature, with doxorubicin, a clinically
widely-used topoisomerase II poison, being described as inactive
(Venditti, 1975). F 11782 exhibited marked and highly significant
antitumour activity against this model, both in terms of increased
life span and tumour growth inhibition, representative of a high
level of activity, according to standard criteria reflected by T/C
ratios of < 10% (Bissery et al, 1991). This activity was achieved
with a single dose, four daily injections or intermittent treatments
over two weeks. Superior activity resulted from the intermittent
treatments over two weeks, with four dose levels providing statis-
tically significant results, reaching levels of P < 0.001, and tumour
growth inhibitions of 76–99.8%. Multiple treatments over two
weeks also allowed administration of the highest total dose of
480 mg/kg, 1.5-fold higher than that permitted using the other
schedules. F 11782 induced body weight loss in excess of 15% in
these B16 tumour-bearing mice at the highest dose tested, without
any apparent toxicity over the range of 20–80 mg/kg/injection,
indicative of a good overall tolerance to F 11782. This activity was
again markedly superior to that noted with etoposide, tested
concurrently.
Against the experimental pulmonary B16F10 melanoma metas-
tases model F 11782 induced a marked dose-dependent reduction
of B16F10 metastatic foci number in the lungs, indicating that it is
capable of potently inhibiting their lung colonization.
In spite of experimental limitations and considerable expense,
the nude mouse–human tumour model has become widely inte-
grated into evaluation of and screening for new compounds and
therapies, and has proved a valuable model (Fiebig et al, 1992;
Langdon et al, 1994). MX-1 breast cancer xenografts were previ-
ously shown to be predictive of human response to anticancer
drugs (Plowman et al, 1997). The present study has shown that F
11782 induced a major and sustained high level of antitumour
activity against advanced-staged MX-1 (breast) tumour
xenografts, with T/C ratios < 10% being recorded, and long-
lasting definite tumour regressions being recorded. Tumour
regressions in animal experimental tumour models are considered
an important end-point of clinical relevance (Plowman et al,
1997). These effects were noted without any significant body
weight changes, indicating that in these models too treatments
with F 11782 were well tolerated. Against early-stage LX-1 (lung)
xenografts, F 11782 also showed definite antitumour activity, as
reflected by a maximal tumour growth inhibition of 81%, which
again was not associated with any significant body weight loss. A
direct comparison with etoposide tested concurrently showed clear
Antitumour activity of F 11782, a dual topoisomerase inhibitor 1523
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superiority for F 11782 against both MX-1 and LX-1 tumour
xenografts. Only modest sensitivity to etoposide or etopophos was
reported earlier using this LX-1 model (Rose et al, 1990), whilst a
lack of activity for etoposide was claimed using a qdx5 schedule
and the i.v. route by Utsugi et al (1996). In addition, doxorubicin
has been described as inactive, when given as i.p. intermittent
doses, in both the MX-1 and LX-1 models (Ovejera and Houchens
1981). More recently, inactivity for doxorubicin against the MX-1
xenografts has also been reported, with an optimal T/C value of
55% resulting from a single i.v. drug administration (Pratesi et al,
1996).
Therefore, the results of this preclinical in vivo study show that
F 11782 exhibited marked activity against a panel of experimental
tumours with different biological properties and chemosensitivi-
ties. This activity was obtained consistently over a wide range of
2–6 dose levels without major toxicity, as judged by monitoring
body weight loss or early deaths, demonstrating overall a high
level of tolerance to F 11782 and suggesting a high therapeutic
index. F 11782 has been selected for preclinical development and
Phase I clinical trials are scheduled to commence at the end of
2000. In the meantime detailed pharmacokinetics as well as
toxicological studies are underway.
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